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GINA: A GENETIC INFORMATION NONDISCRIMINATION
SOLUTION IN SEARCH OF A PROBLEM
Patricia Alten*
ABSTRACT
Genetic discrimination is unfair to workers and their families. It is
unjustified—among other reasons, because it involves little more than
medical speculation. A genetic predisposition toward cancer or heart
disease does not mean the condition will develop. To address the potential
use of genetic information by employers to discriminate against
employees, Congress enacted the Genetic Information Nondiscrimination
Act of 2008 (GINA). This Note proposes the need for modifications to
GINA before it is effective in late 2009. In its current state, the provisions
relating to employers are overly broad and could catch many employers in
unknowing violations. Although GINA prohibits employment
discrimination, it does not cover all of America’s workers and may be
inherently unfair when applied to those it does cover.
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I. INTRODUCTION
“You’re fired.”
Terri Seargent was stunned to hear she was losing her job five days
before Christmas.1 It had only been a month since her supervisor had given
her an outstanding performance review, along with her third raise in three
years.2 She had been a rising star at the company when she was abruptly
told that her “services were no longer needed.”3
Puzzled and angry, Terri wondered what motivated her sudden
dismissal. Terri speculated that perhaps her recently diagnosed genetic
disorder was the cause of her termination.4 Earlier in the spring, Terri’s
allergy-like symptoms caused her doctor to suspect she suffered from
Alpha-1 Antitrypsin Deficiency,5 the same hereditary lung disorder that
had taken her brother’s life.6 Her doctor suggested augmentation therapy,
an expensive treatment.7

1. Dep’t of Health & Human Servs., Nat’l Human Research Prots. Advisory Comm.
(NHRPAC) Meeting 1, 295 (Apr. 9, 2001) [hereinafter NHRPAC Meeting] (testimony of Terri
Seargent).
2. Id. at 294–95 (testimony of Terri Seargent).
3. See id. at 295 (testimony of Terri Seargent).
4. Id. at 295–96 (testimony of Terri Seargent).
5. Alpha-1 Antitrypsin Deficiency is a hereditary condition that predisposes affected
individuals to liver and lung disease. See AlphaNet, FAQs, http://www.alphanet.org/faqs/?c=01FAQs-about-Alpha-1-Antitrypsin-Deficiency (last visited Feb. 17, 2009). Although Alpha-1
Antitrypsin Deficiency is generally thought of as an extremely rare condition, it is actually one of
the most common and serious genetic conditions passed through heredity. See AlphaNet Big Fat
Reference Guide, Alpha-1 Antitrypsin Deficiency: What the Heck Is It Anyway?, http://www.alpha
netbfrg.org/BFRG.aspx?ID=1142 (last visited Feb. 17, 2009).
6. NHRPAC Meeting, supra note 1 at 294 (testimony of Terri Seargent).
7. Augmentation therapy products are made from plasma donation. Augmentation therapy
infusions reduce lung function decline in Alpha-1 patients, “and, therefore, improve the long-term
quality of life and even the lifespan of individuals with Alpha-1.” See AlphaNet Big Fat Reference
Guide, My AlphaNet, http://www.alphanetbfrg.org/AskMedical.aspx (last visited Feb. 17, 2009).
Fortunately, Terri learned of her condition early enough to start treatment which would alleviate
her symptoms and allow her to “continue to live a productive life.” NHRPAC Meeting, supra note
1 at 294 (testimony of Terri Seargent).
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“[The augumentation therapy] was a way to keep from dying,” she later
testified to the Department of Health & Human Services.8 Terri added,
“[t]hat decision cost me my job[,] and my family our middle-class
lifestyle.”9
Although genetic discrimination is not a new concept in the United
States,10 dramatic advances in genetics research have far outpaced
lawmakers’ ability to address its social, ethical, and legal implications.11
The existing patchwork of federal laws and inconsistent state laws left
some individuals without protection. Without a federal law guaranteeing
privacy of genetic health information employers and health insurers could
use the results of genetic tests to discriminate against employees who
might become costly health risks.12 Fueled by growing public concern,13
anecdotal stories of genetic discrimination such as Terri’s, and urged by a
lobby of research scientists unable to find willing subjects, Congress began

8. NHRPAC Meeting, supra note 1 at 294 (testimony of Terri Seargent). The genetic test
provided her with an option her brother never had, and may have even saved her life. See id.
(testimony of Terri Seargent).
9. Id. (testimony of Terri Seargent).
10. Some of the most famous words in America’s history on genetic discrimination are found
in a Supreme Court opinion upholding the eugenic sterilization of eighteen-year-old mentallyhandicapped Carrie Buck in Buck v. Bell, 274 U.S. 200, 205, 208 (1927). Justice Holmes stated:
“It is better for all the world, if instead of waiting to execute degenerate offspring for crime, or to
let them starve for their imbecility, society can prevent those who are manifestly unfit from
continuing their kind . . . . Three generations of imbeciles are enough.” Id. at 207.
11. See generally NAT’L INSTS. OF HEALTH, U.S. DEP’T OF HEALTH & HUMAN SERVS.,
HUMAN GENOME PROJECT: FACT SHEET 1, available at http://www.nih.gov/about/researchresults
forthepublic/HumanGenomeProject.pdf (stating the project “supported an Ethical, Legal and Social
Implications research program to address the many complex issues that might arise from this
science”). Researchers today can locate a gene suspected of causing a disease in a matter of days.
Id. Over 1,000 genetic tests are currently available, and within a few years researchers expect to
find genetic factors for heart disease and mental illness as well. Id. at 1–2. Some of the issues facing
genetic researchers include protecting the privacy of individual genetic information, protecting
individuals from discrimination in health insurance and in the workplace, the ethical conflicts
between a physician’s duty to his patient or duty to warn the family members of a disease they may
contract but has not manifested, and the question of whether patients should share in the royalties
for research successes. Nat’l Human Genome Inst., Ethical, Legal and Social Implications (ELSI)
of Genetic Knowledge, multimedia video and ELSI Vignettes, http://www.genome.gov/25019880
(last visited Feb. 17, 2009).
12. See, e.g., Genetic Discrimination: EEOC’s First Genetic Testing Challenge Settled for
$2.2 Million, Parties Announce, 90 DAILY LAB. REP. (BNA, Arlington, Va.), May 9, 2002, at A–1.
13. See, e.g., SEC’Y’S ADVISORY COMM. ON GENETICS, HEALTH, & SOC’Y, U.S. DEP’T OF
HEALTH & HUMAN SERVS., PUBLIC PERSPECTIVES ON GENETIC DISCRIMINATION 9–11 (Sept.––Nov.
2004), available at http://oba.od.nih.gov/oba/sacghs/reports/Public_Perspectives_GenDiscrim.pdf
[hereinafter PUBLIC PERSPECTIVES] (testimony of Rebecca L. Fisher) (describing Fisher’s fears that
her daughter will be required someday to take a genetic test revealing that she carries the BRCA-1
genetic marker for breast cancer that could result in the loss or denial of either or both employment
and health insurance).
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discussions of proposed federal bills protecting workers against misuse of
genetic data by employers and insurers in 1995.
Finally, in May 2008, President George W. Bush signed the Genetic
Information Nondiscrimination Act of 2008 (GINA) into law.14 Applauded
as the first civil rights law of the twenty-first century,15 and, arguably, the
first major civil rights act to protect workers in nearly two decades since
the Americans with Disabilities Act of 1990 (ADA) was enacted,16 GINA
appears to be a victory in the battle for individual worker rights. GINA
prohibits insurance companies and employers from requiring genetic
information from individuals17 or from discriminating on the basis of
genetics.18 But a closer reading of the law raises questions: Will GINA
really protect workers? Or, will it force the situation into an unwieldy
framework, “a bit like a mean stepsister trying to push her big foot into one
of Cinderella’s tiny glass slippers[?]”19
This Note discusses how GINA does not benefit workers or employers;
protection is erratic at best, unevenly applied, and limited in scope. Part II
of this Note addresses genetic testing, consumer fears about loss of health
insurance, and the need for federal protection against genetic
discrimination. Part III analyzes GINA’s interaction with other federal
laws protecting workers, and the protections GINA itself will offer
workers. Part IV describes the impact on employers and makes
recommendations for insuring compliance. Part V proposes a framework
for plaintiffs seeking remedies and relief under GINA and outlines the
reasons that GINA fails to protect workers.
II. BACKGROUND AND THE NEED FOR GINA
“Humanity’s newly acquired ability to map and understand its own
genetic traits” is a discovery that has “transform[ed] both science and
society.”20 When the Human Genome Project began in 1990,21 optimism

14. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881
(to be codified as amended in scattered sections of 26, 29, 42 U.S.C.).
15. See Press Release, Senators Edward M. Kennedy, Mike Enzi, & Olympia Snowe,
Kennedy, Enzi, Snowe Celebrate Passage of Genetic Information Nondiscrimination Act (Apr. 24,
2008), available at http://kennedy.senate.gov/newsroom/press_release.cfm?id=478F718E-C1994E4F-9105-23442FA86B71.
16. Americans with Disabilities Act of 1990, Pub. L. No. 101-336, 104 Stat. 327 (codified
as amended in scattered sections of 42, 47 U.S.C.).
17. 29 U.S.C.A. § 1182(c)(1) (West 2008).
18. Id. § 1182(b).
19. Dewitt v. Proctor Hosp., 517 F.3d 944, 948 (7th Cir. 2008) (describing the difficulty of
trying to fit genetic discrimination claims under the ADA).
20. S. REP. NO. 110-48, at 5 (2007).
21. NAT’L INSTS. OF HEALTH, U.S. DEP’T OF HEALTH & HUMAN SERVS., HUMAN GENOME
PROJECT: FACT SHEET, supra note 11, at 1. The Human Genome Project was a joint effort by the
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was boundless—researchers would have the means to look for cures to
diseases, doctors would provide better medical advice, and patients, armed
with advanced knowledge of a predisposition for a health problem, would
seek preventative care.22 By 2003, when the exact sequence of the human
genome was decoded,23 some individuals had already experienced what
Congress would recognize as a danger—a person’s very intimate genetic
code being “used for harmful purposes . . . . [For instance, an] employer
might use information about an employee’s genetic profile to deny
employment to an individual who is healthy and able to do the job.”24
Genetic research into relationships between genetic markers25 and “nonmedical conditions, such as intelligence and personality traits” present an
even greater challenge to lawmakers as researchers continue to explore the
vast possibilities unveiled by the Human Genome Project.26 Genetic tests
are available for over 1,000 different markers for diseases and range in
price from $200 to $3,000.27 Genetic data reveals very personal details
about an individual, including intimate facts the individual did not already
know—from personal identification to biological relationships to health
factors.28 The data revealed is not limited to the individual who is tested;
test results disclose intimate data and “important biological facts
about . . . parents, siblings, and children.”29 Public concerns about
misinterpretations of diagnoses, lack of available options until and unless
the disease actually manifests, and personal stories of discrimination by
insurers and employers, led Congress to begin deliberations on federal
protections for citizens.30

National Institutes of Health (NIH), the Department of Energy (DOE), and international partners
to sequence all three billion letters in the human DNA. Id. The goal of the project was to provide
researchers with the ability to find genetic markers to diseases in human DNA, thus enabling them
to develop cures, earlier diagnoses, and innovative prevention tactics. Id.
22. See S. REP. NO. 110-48, at 5.
23. NAT’L INSTS. OF HEALTH, U.S. DEP’T OF HEALTH & HUMAN SERVS., HUMAN GENOME
PROJECT: FACT SHEET, supra note 11, at 1.
24. S. REP. NO. 110-48, at 5–6.
25. A genetic marker is a gene which has an easily identifiable characteristic and can be used
to mark “cell nuclei or chromosomes so that they can easily be isolated or identified from other
nuclei or chromosomes later.” Mondofacto Online Medical Dictionary,
http://www.mondofacto.com/facts/dictionary?query=genetic+marker&action=look+it+up (last
visited Jan. 25, 2009).
26. See NAT’L INSTS. OF HEALTH, U.S. DEP’T OF HEALTH & HUMAN SERVS., HUMAN
GENOME PROJECT: FACT SHEET, supra note 11, at 2.
27. Human Genome Project Information, Gene Testing, http://www.ornl.gov/sci/techresou
rces/Human_Genome/medicine/genetest.shtml (last visited Feb. 17, 2009).
28. Lawrence O. Gostin, Health Information Privacy, 80 CORNELL L. REV. 451, 491 (1995).
29. Id.
30. See S. REP. NO. 110-48, at 1, 6–8.
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When Terri was fired, she lost more than just a nice income, she also
lost the health insurance that helped pay for the very expensive treatments
she needed to keep her alive.31 Once she was labeled with the Alpha-1
gene, she became uninsurable, and her family’s savings were quickly
depleted in order to pay for her treatments.32 As Terri’s story demonstrates,
genetic discrimination directly impacts an individual’s employment
opportunities, as well as her ability to obtain health insurance, disability
insurance, and life insurance.
For most Americans, “the ticket to health care services of any kind or
quality” is through health insurance coverage.33 Most Americans rely on
their jobs for health insurance.34 Without a job or health insurance benefits,
treatment and medication for a disease resulting from a genetic disorder is
probably unaffordable for the average American. Genetic discrimination
not only affects the ability of those afflicted with a genetic disorder to
access health care, it also has a dramatic impact on the probability that
future generations will be denied health care and employment if they are
labeled with defective genes or labeled as carriers.
Phil Hardt and his family know all too well the impact of genetic
labeling.35 Unlike Terri, Phil managed to avoid losing his job despite
diagnoses of hemophilia B and Huntington’s Disease.36 However, hiding
his afflictions from his supervisor was only the beginning of his battle with
genetic discrimination which eventually extended to three generations of
his family.37 For almost four decades, Phil, his children, and his
grandchildren were denied all types of insurance due to their genetic

31. See NHRPAC Meeting, supra note 1, at 296 (testimony of Terri Seargeant).
32. Id. at 295–97 (testimony of Terri Seargeant).
33. Robert H. Jerry, II, Life, Health, and Disability Insurance: Understanding the
Relationships, 35 J.L. MED. & ETHICS 80, 82 (Supp. 2007).
34. See HENRY J. KAISER FAMILY FOUND., Summary of Findings, EMPLOYER HEALTH
BENEFITS 2008 ANN. SURV. 1 (2008), available at http://ehbs.kff.org/pdf/7791.pdf [hereinafter
EMPLOYER HEALTH BENEFITS].
35. See PUBLIC PERSPECTIVES, supra note 13, at 23–36 (testimony of Phil Hardt).
36. Id. at 23 (testimony of Phil Hardt). For more information on Hemophilia B, see generally
Nat’l Hemophilia Found., Hemophilia B (Factor IX), http://www.hemophilia.org/NHFWeb/Main
Pgs/MainNHF.aspx?menuid=181&contentid=46 (last visited Feb. 26, 2009). Hemophilia B is a
bleeding disorder that occurs in one in 25,000 male births. Id. Hemophilia is usually inherited, but
approximately 30% of the time it results when there is no familial history. Id. For more information
about Huntington’s Disease, see generally Huntington’s Disease Soc’y of Am., What is
Huntington’s Disease (HD)?, http://www.hdsa.org/about/our-mission/what-is-hd.html (last visited
Feb. 17, 2009) (describing Huntington’s Disease (HD) as “a devastating, hereditary, degenerative
brain disorder for which there is, at present, no effective treatment or cure”). Huntington’s Disease
is a degenerative disease that “slowly diminishes the affected individual’s ability to walk, think,
talk and reason.” Id.
37. PUBLIC PERSPECTIVES, supra note 13, at 23–24 (testimony of Phil Hardt).
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diagnoses.38 Even before his diagnosis of Huntington’s, insurers denied
him credit insurance.39 After his divorce, he was denied long term-care
insurance when he most needed someone to care for him.40 His daughter
was denied life insurance and mortgage life insurance because of Phil’s
diagnosis and was told by the insurance companies that she could not
purchase coverage unless she provided negative test results for the
Huntington’s gene.41
Stories like Phil’s and Terri’s reached lawmakers. To learn about the
public’s fears of discriminatory treatment, Congress conducted public
hearings about genetic testing.42 Individuals wrote, emailed, faxed, and
testified about experiences with discrimination in health insurance and
many voiced genuine concern that employers might discriminate in the
interest of cutting health care costs.43
Congress determined that existing laws did not adequately protect the
public from potential genetic discrimination.44 For example, while an
insurer could not charge one individual in a group a higher premium than
the rest of the group based on genetic information,45 the insurer was free
to establish premiums for the entire group based on genetic information of

38. Id. at 24 (testimony of Phil Hardt).
39. Id. (testimony of Phil Hardt).
40. Id. at 24, 33–36 (testimony of Phil Hardt).
41. Id. at 24, 29–32 (testimony of Phil Hardt). Because of the blatant genetic discrimination
that Phil Hardt and his eldest daughter experienced when trying to purchase insurance, Phil worked
with a Tucson geneticist and the Arizona chapter of the Huntington’s Disease Society of America
to establish an anonymous testing procedure for his other children. Id. at 24 (testimony of Phil
Hardt). He has also helped others in his support group to get similar testing. Id. at 24, 27 (testimony
of Phil Hardt). Under the testing, “[t]he person uses a bogus name, address, phone and social
security number and pays cash to find out anonymously if they have HD . . . .” Id. at 27 (testimony
of Phil Hardt). Although the subterfuge is expensive, the results don’t go into the patient’s medical
record or medical database. Id. at 26 (testimony of Phil Hardt). Then, if a person finds out they have
the gene for Huntington’s, “[she] can get all of the necessary insurances before they become
symptomatic.” Id. at 27 (testimony of Phil Hardt).
42. See generally PUBLIC PERSPECTIVES, supra note 13 (providing the testimonies by those
having faced alleged genetic discrimination given to the Secretary’s Advisory Committee on
Genetics, Health, and Society). For example, Tonia Phillips, who has the genetic marker for breast
and ovarian cancer (BRAC-1), was asked by her boss to switch to her husband’s insurance. Id. at
14 (written comment of Tonia Phillips). In another situation, Paula Funk’s doctors advised her
against genetic testing for BRAC-1, despite a strong familial history for breast cancer. She tested
anyway, hoping that if she paid directly her insurer would not have access to her genetic tests.
When she tested positive and needed to justify expensive screening tests, the insurer had access to
the information and her insurance rates increased $100 a month. Id. at 16-19 (written comment of
Paula Funk).
43. See generally PUBLIC PERSPECTIVES, supra note 13.
44. See S. REP. NO. 110-48, at 10–15.
45. Id. at 9–10.
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one individual.46 The health insurance industry argued that for accurate risk
assessment in small- to mid-sized groups, insurers must be permitted to
rate policies based on the highest risk individuals.47 Congress also
criticized the Health Insurance Portability and Accountability Act
(HIPAA)48 because it applied only to insurance companies writing group
health policies and exempted insurance companies writing policies for
individuals.49
In light of the limitations of existing laws and testimony before various
committees of the House and Senate, the Senate Committee on Health
Education, Labor, and Pensions concluded in its report that new federal
legislation was needed to protect individuals from potential genetic
discrimination in health insurance and employment.50
III. THE LAWS GOVERNING GENETIC DISCRIMINATION
A. Federal Law Predating GINA
Prior to the enactment of GINA, three federal laws and a presidential
order provided limited federal protection against genetic discrimination.
Title VII of the Civil Rights Act of 1964 (Title VII),51 provided “no
obvious protection against genetic discrimination,” although an employee
might find indirect protection if an employer used genetic information to
discriminate on the basis of “race, color, religion, sex, or national origin.”52
The primary federal laws protecting against genetic discrimination are
based on health rather than visible factors of discrimination found under
Title VII. The ADA does not specifically discuss genetic discrimination
but the EEOC has stated that employees could find protection under one
of the ADA’s three prongs.53 For individuals who have not manifested

46. Id. at 10.
47. Genetic Non-Discrimination: Implications for Employer Provided Health Care Plans:
Hearing Before the Subcomm. on Employer-Employee Relations of the H. Comm. on Education and
the Workforce, 107th Cong. 33–37 (2001) (statement of Janet Trautwein, Director of Federal Policy
Analysis and State Government Affairs, National Association of Health Underwriters).
48. Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110
Stat. 1936 (codified as amended in scattered sections of 18, 26, 29, 42 U.S.C.).
49. S. REP. NO. 110-48, at 10 (2007).
50. Id. at 10, 13–15.
51. 42 U.S.C. §§ 2000e–17 (2006). Exec. Order No. 13,145, 65 Fed. Reg. 6,877 (Feb. 8,
2000).
52. S. REP. NO. 110-48, at 11 (2007).
53. Americans with Disabilities Act of 1990, Pub. L. No. 101-336, 104 Stat. 327 (codified
as amended in scattered sections of 42, 47 U.S.C.). The term “disability” with respect to an
individual is defined with three prongs as: “(A) a physical or mental impairment that substantially
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symptoms, the prong would likely be the “regarded as” prong which
protects an employee when an employer mistakenly believes that an
employee has a substantially limiting physical disability or mistakenly
believes the employee’s disability limits activities more than it really
does.54 Congress’s intent in crafting the “regarded as” prong was to protect
individuals who might be denied employment based on “‘myths, fears and
stereotypes associated with disabilities.”55 Terri’s claim of discrimination
against her employer was filed under this prong of the ADA.56
Terri’s firing arose as a result of her doctor’s disclosure of her
confidential medical information to her employer.57 Doctor-patient
confidentiality, once sacred, has become a confusing conundrum of laws,
acronyms, misunderstandings, and fear of litigation.58 The advancement of
genetic knowledge, in tandem with rapidly-increasing development in
technology, poses compelling privacy concerns.59 HIPAA might have
provided Terri with a cause of action against her employer.60 HIPAA
serves dual functions to protect participants of group health plans. One
function is protecting the privacy of a patient’s confidential medical
information by prohibiting covered entities from protected health

limits one or more of the major life activities of such individual; (B) a record of such an
impairment; or (C) being regarded as having such an impairment.” See Nat’l Workrights Inst., The
ADA’s Definition of “Disability,” http://www.workrights.org/issue_genetic/gd_ada.html (last
visited Feb. 17, 2009). See also Tresa Baldas, Legal Tension Grows Over Genetic Tests: Privacy,
Potential Discrimination are Major Concerns, 28 NAT’L L. J., Oct. 31, 2005, at 1.
54. See Nat’l Workrights Inst., supra note 53.
55. Sutton v. United Air Lines, Inc., 527 U.S. 471, 489–90 (1999) (quoting 29 C.F.R. pt.
1630, App. § 1630.2(l) (2008)).
56. See NHRPAC Meeting, supra note 1, at 297 (testimony of Terri Seargent). Terri’s claim
was settled by the EEOC before suit. Id. (testimony of Terri Seargent). Although Terri testified that
she was considered under the second prong, “regarded as being disabled” is generally considered
the third prong of the ADA.
57. NHRPAC Meeting, supra note 1, at 295 (testimony of Terri Seargent).
58. See JUNE M. SULLIVAN, HIPAA: A PRACTICAL GUIDE TO THE PRIVACY AND SECURITY
OF HEALTH DATA 2 (2004).
59. See Gostin, supra note 28, at 491–92.
60. HIPAA’s privacy protection is limited. S. REP. NO. 110-48, at 9–10 (2007). HIPAA does
not apply to medical providers who do not submit forms in electronic format, nor does it apply to
group health plans with fewer than fifty participants, employer self-insured plans that are
administered by the employer, or health insurers writing individual policies. 45 C.F.R. § 160.103
(2006); see also SULLIVAN, supra note 58, at 4. Although fines and criminal penalties are
established for disclosing protected information, “HIPAA does not require [covered] entities to
notify individuals after unauthorized or wrongful disclosure of individually identifiable health
information” has occurred. Brandon Faulkner, Note, Hacking into Data Breach Notification Laws,
59 FLA. L. REV. 1097, 1116 (2007). In fact, Congress may have omitted the notification requirement
because they may have “viewed the issue as a personal information privacy matter, rather than an
identity theft issue.” Id.

Published by UF Law Scholarship Repository, 2009

9

Florida Law Review, Vol. 61, Iss. 2 [2009], Art. 6

388

FLO RID A LAW REVIEW

[V ol. 61

information without a patient’s authorization.61 HIPAA also assures the
portability of health insurance coverage, enabling individuals to change
health carriers after a change of job without denial or increased rates based
on pre-existing conditions.62 It is in this area that HIPAA provides “some
protection against discriminatory practices in health insurance based on an
individual’s genetic information.”63
B. And Along Comes GINA
GINA, which will be effective in late 2009, covers two broad areas of
genetic discrimination: health insurance coverage and employment.64
Health insurance and employment are frequently tied together because
most Americans rely on their employers for health insurance. GINA’s Title
II prohibits employment discrimination65 by employers,66 labor unions,67
employment agencies,68 and training programs.69 GINA prohibits
discrimination in hiring, discharge, or with respect to compensation, terms,
or privileges of employment based on genetic information.70 Further, it is
unlawful for employers to acquire genetic information about an employee

61. 45 C.F.R. pts. 160, 164 (2002).
62. S. REP. NO. 110-48, at 9–10.
63. Id. at 9.
64. This Note discusses only Title II of GINA. Title I of GINA prohibits health insurers from
underwriting policies or adjusting premiums in a health insurance plan based on genetic test results
of any individual or family member of an individual covered in a plan. Genetic Information
Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881 (to be codified as amended in
scattered sections of 26, 29, 42 U.S.C.). Insurers cannot require an individual or a family member
to undergo a genetic test. Further, insurers cannot request, require, or purchase information about
an individual for underwriting purposes prior to enrollment. Id. §§ 101–106 (to be codified as
amended in scattered sections of 26, 29, 42 U.S.C.). Members of the health insurance industry have
suggested that “section 101 . . . could limit consumer access to life-saving treatments because it
prohibits health insurance plans from ‘requesting or requiring’ an individual . . . to undergo a
genetic test . . . even when it is needed to determine the appropriate course of treatment and
evaluate the patient’s eligibility for coverage.” Hearing on Genetic Non-Discrimination: Hearing
Before the Subcomm. on Health of the H. Comm. on Ways and Means, 110th Cong. (2007)
(statement of William D. Corwin, M.D., Medical Director, Clinical Policy, Harvard Pilgrim Health
Care on behalf of America’s Health Insurance Plans). Because of rapid and unforeseen advances
in medicine, insurers urged Congress to consider that the future might hold many legitimate
circumstances where health insurers would need to request genetic testing for the benefit of the
patient and that the language of GINA is too limiting to permit insurers to request these tests. Id.
65. Id. §§ 201–213 (to be codified as amended in scattered sections of 42 U.S.C.).
66. Id. § 201(2)(B) (to be codified at 42 U.S.C. § 2000ff(2)(B)).
67. Id. § 201(2)(C) (to be codified at 42 U.S.C. § 2000ff(2)(C)).
68. Id.
69. Id. § 205 (to be codified at 42 U.S.C. § 2000ff-4(a)). Throughout the balance of this Note,
the term “employers” will refer to any of these organizations.
70. Id. § 202(a)(1) (to be codified at 42 U.S.C. § 2000ff-1(a)(1)).
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or an employee’s family member, except under certain conditions.71
Employers who acquire or possess confidential genetic information about
an employee are required to treat the genetic information as part of a
confidential medical record and maintain it separately.72 Treating
confidential information in the same manner as confidential ADA medical
records ensures that employers are in compliance.73 Employers may not
disclose genetic information, except to the employee at the employee’s
written request or in certain other limited circumstances.74
IV. GINA’S IMPACT ON THE WORKPLACE
A. Employer Concerns
Employers argued vehemently against GINA.75 Its remedial measures
and punitive clauses leave employers vulnerable to stiff fines and lawsuits
from employees. Employers were concerned that as new genetic markers
are discovered, the broad language in previous versions of GINA might
result in employees demanding that employers provide health coverage for
every possible genetic disorder.76 GINA does not limit the use, acquisition,
possession, or disclosure of genetic information to asymptomatic or
predictive information, therefore, employers could easily find themselves
in violation of collecting information from applicants or employees about
family members. Another problem facing employers is that the statute does
not address what employers are to do with any non-medical personnel
records containing familial medical data.
Conflicts with existing state and federal laws could prove to be another
potential pitfall for employers. Currently, thirty-four states and the District
of Columbia have existing laws prohibiting genetic discrimination and
several states have enacted legislation prohibiting the disclosure of genetic

71. See id. § 202(b) (to be codified at 42 U.S.C. § 2000ff-1(b)). Exceptions include:
inadvertence; written consent of the employee; disclosure by a genetic counselor providing services
to the employee; compliance with the Family and Medical Leave Act of 1993; purchase of
documents that are commercially and publicly available; biological effects of toxic substances in
the workplace with additional conditions; and if the employer conducts DNA analysis for law
enforcement or other purposes, and then only to exclude employees from sample contamination.
Id.
72. Id. § 206(a) (to be codified at 42 U.S.C. § 2000ff-5(a)).
73. Id.
74. Id. § 206(b) (to be codified at 42 U.S.C. § 2000ff-5(b)).
75. See Protecting Workers from Genetic Discrimination: Hearing Before the Subcomm. on
Health, Employment, Labor, and Pensions of the H. Comm. on Education and Labor, 110th Cong.
49 (2007) (statement of Burton J. Fishman, Partner, Fortney Scott, LLC, Genetic Information
Nondiscrimination in Employment (GINE) Coalition).
76. GINA’s § 209(a)(7) should relieve some of employers’ concerns. Genetic Information
Nondiscrimination Act of 2008, § 209(a)(7) (to be codified as amended in 29 U.S.C. § 1182(d)(1)).
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information without the owner’s consent.77 Employers are concerned that
Congress did not adequately consider potential conflicts with existing laws.
A major concern to both employers and insurers is GINA’s definition
of “genetic test” as “an analysis of human DNA, RNA, chromosomes,
proteins, or metabolites, that detects genotypes, mutations, or
chromosomal changes.”78 In congressional hearings and reports submitted
to Congress, employers and representatives of the health insurance industry
objected to the definition in the proposed versions of the law as overly
broad and vague.79 The health insurance industry recommended the
definition of “genetic test” be limited to predictive testing performed on
asymptomatic or undiagnosed individuals for the purposes of assessing the
risk of future disease.80
Employer groups and insurance industry representatives argued that the
“current definition of genetic test[ing] . . . could serve to prohibit items like
cholesterol tests, performed to detect symptoms, clinical signs or a
diagnosis of disease. It could also hinder current and advancing methods
of detecting cancer.”81 The definition of “genetic test” could also increase
medical liability for health care providers who may not meet an arbitrary
standard of care.82 However, Congress did not listen to the scientists and

77. Bill Leonard, The Stealth Statute, HR MAGAZINE 47, 48 (Dec. 2008). See, e.g., ALASKA
STAT. §§ 18.13.010-18.13,100 (permitting a private cause of action for actual damages along with
statutory damages of either $5,000 or $100,000 (§ 18.13.020)); CAL. INS. CODE § 10149.1; NEV.
CODE ANN. §§ 629.101–629.201.
78. Id. § 101(d)(7)(A) (to be codified as amended in 29 U.S.C. § 1191b(d)(7)(A)).
79. Statement from Janet Stokes Trautwein, Executive Vice President and CEO, National
Association of Health Underwriters, for the House Committee on Education and Labor Regarding
H.R. 493: The Genetic Information Nondiscrimination Act of 2007 (Feb. 14, 2007), available at
http://www.nahu.org/legislative/genetic/GeneticsEdLaborStatement.pdf [hereinafter Trautwein
2007 Written Statement]. The statement is extremely broad, even with the exceptions that a genetic
test is not "an analysis of proteins or metabolites that does not detect genotypes, mutations, or
chromosomal changes,” nor is it “an analysis of proteins or metabolites that is directly related to
a manifested disease, disorder, or pathological condition that could reasonably be detected by a
health care professional with appropriate training and expertise in the field of medicine involved.”
Id.
80. Id. The National Association of Health Underwriters (NAHU) proposed the following
language to define genetic test: “analysis of human DNA . . . associated with an increased statistical
risk of development of a disease or disorder, and the analysis is performed for the purposes of
predicting risk of disease or disorders in asymptomatic individuals.” Id. The NAHU also proposed
that the definition contain the following exception: “[that] [s]uch term does not include physical
and chemical tests, such as blood or urine analyses of the individual, including cholesterol tests and
physical exams of the individual, or a test to determine the illegal use of drugs.” Id.
81. Id.
82. Id. Members of the health insurance industry have suggested that some sections of GINA
“could limit consumer access to life-saving treatments because it prohibits health insurance plans
from ‘requesting or requiring’ an individual . . . to undergo a genetic test . . . even when it is needed
to determine the appropriate course of treatment and evaluate the patient’s eligibility for coverage.”
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adopted the ambiguous language of the proposed law. When plaintiff
lawyers look at the broad definition in conjunction with the other benefits
offered by the remedies outlined below, an onslaught of litigation from
employees could result.
B. A Roadmap for Employer Compliance
There is no doubt that GINA will have a significant impact on most
workplaces. To ensure that human resources departments are in
compliance when GINA becomes effective, employers should prepare in
advance. Proper training on the important aspects of the new law for
administrative staff in charge of hiring and benefits management is
essential.
Most employers offering health insurance to employees are likely to
possess some family history information in personnel records. Employers
should review personnel files and employee records and purge all
information that could be construed as genetic information, including
medical information and family histories. Performance reviews, written
reprimands, and file memos should be carefully reviewed for possible
mentions of a familial health problem.
To illustrate how a potential problem could arise, suppose employee A
took bereavement leave to attend the funeral of a relative two years ago.
As part of the employer policy, A provided a copy of the death certificate
in order to be paid for bereavement time. The employer retained the death
certificate with the payroll records, along with the supervisor’s memo
approving the leave. If the relative falls within the four degrees of
generations described in the statute and the cause of death listed is one that
is known to have genetic markers, or is discovered in the future to have
genetic markers, then A may have a cause of action if he is terminated.
A second illustration demonstrates how innocent comments in
personnel files by supervisors or employees could pose a potential problem
under GINA. Suppose last year employee B’s supervisor reprimanded B,
an employee with mediocre performance, about a recent problem with
tardiness. In her comments in the file memo, the supervisor noted that B’s
reason was because B’s mother’s work schedule had changed, so B had
become responsible for giving her diabetic brother his shots in the morning
before taking him to school. The supervisor counseled B and allowed her
Hearing on Genetic Non-Discrimination: Hearing Before the Subcomm. on Health of the H. Comm.
on Ways and Means, 110th Cong. (2007) (statement of William D. Corwin, M.D., Medical
Director, Clinical Policy, Harvard Pilgrim Health Care on behalf of America’s Health Insurance
Plans). Because of rapid and unforeseen advances in medicine, insurers urged Congress to consider
that the future might hold many legitimate circumstances where health insurers would need to
request genetic testing for the benefit of the patient and that the language of GINA is too limiting
to permit insurers to request these tests. Id.
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to adjust her work hours to accommodate the additional family
responsibilities. In this reference, genetic markers for diabetes have been
disclosed, thus B may have a cause of action.
Employers with multiple locations will need to understand what impact
GINA will have on the various state laws and federal statutes already in
effect.83 There is an exception in GINA for obtaining information for leave
under the Family Medical Leave Act (FMLA). However, employers must
be careful not to confuse gathering information to support FMLA leave
with obtaining it for employer-sponsored leave, which would be a violation
of GINA. Similarly, employers should carefully review their practices of
gathering information for health insurance and wellness programs to insure
employer procedures are in compliance.84
Employers who are also administrators of the company’s health care
plan face an inherent conflict of interest because of their dual roles. Those
employers should be cautious about denying benefits or terminating plans
“unless the benefit plan gives the administrator or fiduciary discretionary
authority to determine eligibility for benefits or to construe the terms of the
plan.”85 Employers and their human resources professionals should tread
carefully with this new law. GINA’s impact will be felt by many
employers that inadvertently violate its provisions and incur penalties.
V. GINA’S IMPACT ON WORKERS
A. A Proposed Framework for Causes of Action
The EEOC and Department of Labor are in the process of drafting
regulations for the enforcement of GINA.86 Section 207 of GINA provides
remedies for employees who allege unlawful employment practices of
genetic discrimination.87 Nonfederal employees bringing charges of genetic
discrimination against an employer would file a claim with the EEOC
within 180 days of the date of the discriminatory act.88 The date of the

83. Leonard, supra note 77, at 48.
84. Leonard, supra note 77, at 49.
85. Firestone Tire & Rubber Co. v. Bruch, 489 U.S. 101, 115 (1989) (finding the de novo
standard of review applies unless the plan has given the fiduciary authority to set the terms of the
plan, and that any possible or actual conflict of interest will be “weighed as a ‘facto[r] in
determining whether there [has been] an abuse of discretion’” (quoting RESTATEMENT (SECOND)
OF TRUSTS § 187 cmt. d (1959)) (first alteration in original)).
86. Leonard, supra note 77, at 49.
87. Genetic Information Nondiscrimination Act of 2008, § 207 (to be codified at 42 U.S.C.
§ 2000ff-6).
88. 42 U.S.C. § 2000e-5(e)(1) (2006). The deadline is 300 days if an applicable state or local
law also prohibits the discriminatory act. Id.; see U.S. E.E.O.C., Filing a Charge of Employment
Discrimination: What are the Time Limits for Filing a Charge of Discrimination?,
http://www.eeoc.gov/charge/overview_charge_filing.html (last visited Feb. 17, 2009).
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discriminatory act is generally held to be the date an employee is made
aware of a decision involving the employee, not when the decision takes
effect.89 The EEOC will perform an investigation, mediate, and attempt
conciliation.90 If no conciliation is possible, it will issue a “right-to-sue”
letter, giving plaintiff the private right to sue.91 Plaintiffs may then hire
private counsel, who become, in effect, private attorneys general.92
The framework of a genetic discrimination case against an employer
could vary greatly depending on the nature of the discrimination alleged
and the basis of the employer’s knowledge about plaintiff’s genetics. In
general, a plaintiff will make either a direct or an indirect discrimination
case.93 In the direct method, plaintiff would present all circumstantial and
non-circumstantial evidence.94 Defendant would do the same.95 If a
reasonable jury could find discrimination, then the case will survive
summary judgment.96
In McDonnell Douglas Corp. v. Green,97 the Supreme Court established
a burden-shifting test for bringing indirect Title VII discrimination cases.98
Under the McDonnell Douglas framework, plaintiff bears the initial burden
of presenting a prima facie case that he or she (1) is a member of the group
protected by the law; (2) was discriminated against in the course of
employment; (3) is qualified, but was rejected; and (4) the position
remained open and the employer continued to seek applicants from others
with qualifications similar to plaintiff’s.99 Then, the burden of proof shifts
to the defendant-employer to articulate a legitimate, nondiscriminatory
reason for its adverse employment action.100 Plaintiff must then meet the
final burden of proving that the employer’s motives were a pretext.101
Plaintiff’s protected group, under a McDonnell Douglas analysis of
GINA, would include an employee who: (1) had a genetic test; or (2) has

89. See, e.g., Del. State Coll. v. Ricks, 449 U.S. 250, 258–59 (1980) (finding that plaintiff’s
time period for filing began to toll when he was first notified that he would be denied tenure, not
when his contract terminated).
90. 42 U.S.C. § 2000e-5(b) (2006); see also U.S. E.E.O.C., EEOC’s Charge Processing
Procedures, http://www.eeoc.gov/charge/overview_charge_processing.html (last visited Feb. 17,
2009).
91. U.S. E.E.O.C., EEOC’s Charge Processing Procedures, supra note 90.
92. 42 U.S.C. § 2000e-5(f)(1).
93. See, e.g., Dewitt v. Proctor Hosp., 517 F.3d 944, 950 (7th Cir. 2008) (Posner, J.,
concurring).
94. Id.
95. Id.
96. Id.
97. 411 U.S. 792 (1973).
98. Id. at 801–02.
99. Id. at 802.
100. Id.
101. Id. at 804.
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a family member, including a dependent or a first-, second-, third-, or
fourth-degree relative102 who has had a genetic test; or (3) has a family
member, including a dependent or first-, second-, third-, or fourth-degree
relative, who manifests a disease or disorder.103 This relative pool is very
broad, and there is no requirement in the statute that the disease or disorder
manifested by any of the near or distant relatives in the pool is one that has
a known genetic marker.104 Other than the exception noted for
inadvertence, the statute is not specific about an employer’s knowledge of
the employee’s family genetic history and its instrumentality in a
discrimination claim.105 For smaller companies or small towns with one or
two major employers where supervisors know employees and their
families personally, this could be problematic. To mollify employers,
§ 210 adds another limitation—employers will not violate GINA for using
or disclosing “medical information that is not genetic information about a
manifested disease [or] disorder . . . that has or may have a genetic
basis.”106 But, sources of available genetic fodder still remain wide-open.
It is possible that if a plaintiff claimed discrimination based on a family
member’s manifested disease or disorder, a court might analogize the
analysis to a claim under the association discrimination provision of the
ADA. That provision prohibits employers from discriminating against an
employee simply because of the employee’s association or relationship
with a person with a disability.107 Under the ADA analysis, the employer
must know of the relationship and of the other person’s illness in order for
plaintiff to make a prime facie case.108 In Larimer, the court described the

102. First-degree relatives include children and parents; second-degree relatives include
grandparents, siblings, and grandchildren; third-degree relatives include uncles, aunts, nieces,
nephews, great-grandparents, and great-grandchildren; fourth-degree relatives include first cousins,
great-great-grandparents, great-uncles, great-aunts, grandnephews, and grandnieces (i.e., children
of nieces and nephews). JOEL C. DOBRIS, STEWART E. STERK & MELANIE B. LESLIE, ESTATES &
TRUSTS 69 tbl. (3d ed. 2007).
103. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233 §§ 201–202,
122 Stat. 881, 905–07 (to be codified at 42 U.S.C. §§ 2000ff–2000ff-1). In contrast, California’s
corresponding statute defines inherited genetic characteristics as those that: “may derive from the
individual or family member, . . . or that are determined to be associated with a statistically
increased risk of development of a disease or disorder, and that are presently not associated with
any symptoms of any disease or disorder.” CAL. GOV’T CODE § 12926(h)(2)(B) (West 2008).
104. For an up-to-date status on new diseases with genetic markers, see GeneTests, What’s
New in GeneReviews?, http://www.genetests.org (follow “New in GeneReviews” hyperlink) (last
visited Feb. 17, 2009).
105. See Genetic Information Nondiscrimination Act of 2008, § 203(b) (to be codified at 42
U.S.C. § 2000ff-2).
106. Id. § 210 (to be codified at 42 U.S.C. § 2000ff-9).
107. 42 U.S.C. § 12112(b)(4) (2006).
108. See, e.g., Poveromo-Spring v. Exxon Corp., 968 F. Supp. 219, 227 (D.N.J. 1997) (finding
plaintiff’s claim—that he was fired after his mother was diagnosed with a brain ailment and had
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three types of cases that might arise under association-based
discrimination.109 The first type of case relates to the expense of a
disability; for example, when a “spouse has a disability that is costly to the
employer because the spouse is covered by the company’s health plan.”110
The second category is broken into two subsections of disability by
association—one dealing with the employee’s homosexual partner, and the
other dealing with the employee’s blood relative.111 One example given by
the court of this latter subcategory was that “one of the employee’s blood
relatives has a disabling ailment that has a genetic component and the
employee is likely to develop the disability as well.”112 The third category
is the employer’s fear that the employee will be distracted by caring for a
loved one with a disability.113
In Dewitt, a more recent case, the Seventh Circuit suggested the
traditional McDonnell Douglas test is an unwieldy framework for deciding
an association discrimination case by describing it as “a bit like a mean
stepsister trying to push her big foot into one of Cinderella’s tiny glass
slippers.”114 The court argued the McDonnell Douglas framework did not
consider the expense factor of association discrimination discussed by the
Seventh Circuit in Larimer,115 and found it particularly onerous in
Dewitt.116 The court seemed to suggest that the McDonnell Douglas
framework should be tweaked to permit plaintiff to include circumstantial
evidence of the employer’s economic motive in plaintiff’s prima facie
case.117 A form of employment discrimination based on the expensive
employee, or the employee with the expensive dependents, would be
consistent with Congress’s findings that advances in genetics “give rise to
the potential misuse of genetic information to discriminate in health
insurance and employment,”118 and that “employers may come to rely on

a seizure at the same workplace—was sufficient to support a claim of association-based
discrimination for the jury).
109. Larimer v. IBM Corp., 370 F.3d 698, 700 (7th Cir. 2004).
110. Id.
111. Id.
112. Id.
113. Id.
114. Dewitt v. Proctor Hosp., 517 F.3d 944, 948 (7th Cir. 2008).
115. Larimer, 370 F.3d at 701; see Dewitt, 517 F.3d at 947–48 (describing the difficulty the
court experienced in Larimer in trying to adapt the McDonnell Douglas test to the “expense”
category of ADA association discrimination claims).
116. Dewitt, 517 F.3d at 948 (stating that the financial implications of employee’s spouse’s
continued cancer treatments were certainly a factor in her termination).
117. See id. at 951–53 (Posner, J., concurring).
118. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, § 2, 122 Stat.
881, 882 (to be codified at 42 U.S.C. § 2000ff n.).
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genetic testing to ‘weed out’ those employees who carry genes associated
with diseases.”119
Adopting an economic doctrine of employment discrimination is
unnecessary and could be a dangerous precedent. There are already laws
to protect employees from employers trying to withhold benefits.120
Employers are currently free to purchase insurance with caps of liability;
or, for self-insured employers, to cap the liability per employee.121 Further,
a doctrine of economic employment discrimination would lead to an overly
broad interpretation of disability. As the Fifth Circuit noted, “[t]o interpret
‘discrimination’ broadly . . . would clearly conflict with Congress’s intent
that employers remain free to create, modify and terminate the terms and
conditions of employee benefits plans without governmental
interference.”122 This would be a bit like forcing the Prince to marry the
mean stepsister just because she could force her foot into the tiny shoe.

119. S. REP. NO. 110-48, at 6 (2007). A 2004 Medical Testing Survey conducted by the
American Management Association indicates that nearly 63% of employers who responded to the
survey required employees to submit to some type of medical testing. AM. MGMT. ASS’N, AMA
2004 WORKPLACE TESTING SURVEY: MEDICAL TESTING 1, available at http://www.amanet.org/res
earch/pdfs/Medical_testing_ 04.pdf (on file with author). Stories like the public battle between the
National Basketball Association (NBA) and star player Eddy Curry have enhanced public concerns
about genetic testing. See Jim Litke, Curry at Center of “Fight Far Bigger Than Sports,” L.A.
TIMES, Oct. 2, 2005, at D-2. The NBA made headline news when the Chicago Bulls demanded that
its talented center submit to DNA testing for a genetic heart disease. Id. Curry refused the invasive
test and, after months of conflict that played out in the press, was traded to the Knicks without the
test. Michael A. McCann, The Reckless Pursuit of Dominion: A Situational Analysis of the NBA
and Diminishing Player Autonomy, 8 U. PA. J. LAB. & EMP. L. 819, 849 (2006). As a result of the
conflict with Eddy Curry, the NBA now requires mandatory cardiac testing of its athletes. Howard
Beck, The N.B.A. Is the First League to Begin Standardized Cardiac Screening, N.Y. TIMES, Sept.
17, 2006, at 8-5. While not quite the same level of invasiveness as DNA testing, the mandatory tests
still provide the teams with much more information about a player's health and private information
than most individuals want to share. Id. David Stern, the NBA commissioner, justified player
testing as a business investment decision:
If you’re thinking about drafting a player, you do blood [tests], you do X-rays,
skeletal, you look for scars, for breaks, for weaknesses, for disease. I don’t know
what you would be looking for with DNAs [sic], but given the size of the contract
and the importance of the draft pick, I think that diagnostic testing that tells you
whether you’re making a good investment is not a bad idea.
Stern Backs Bulls in DNA Testing of Curry, ESPN.COM, Sept. 30, 2005, http://sports.espn.go.com/
nba/news/story?id=2176913 (first alteration in original) (quoting David Stern, NBA
Commissioner).
120. ERISA would likewise protect employees who learn that they or their dependents have
a genetic disorder. See, e.g., 29 U.S.C. § 1140 (2006).
121. Id. § 1051.
122. McGann v. H & H Music Co., 946 F.2d 401, 407 (5th Cir. 1991) (rejecting plaintiff’s
contention that altering an employee benefits plan which results in an identifiable employee, or
group of employees, being treated differently from other employees, is discriminatory).
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B. Finding Relief Under GINA
Relief for complainants subjected to unlawful employment practices
include rehiring or reinstatement, back pay, back pay plus interest, or other
equitable relief—as well as the issuance of an injunction that prevents the
employer from engaging in further discriminatory practices.123 Title VII
statutory damages include both compensatory and punitive damages.124
“[C]ompensatory damages . . . for future pecuniary losses, emotional pain,
suffering, inconvenience, mental anguish, loss of enjoyment of life, and
other nonpecuniary losses, and the amount of punitive damages” are
limited to a fixed dollar amount, based on the number of employees in a
company.125 Plaintiffs may also request a jury trial.126
The enforcement provisions of Title VII include fee-shifting provisions
allowing for payment of reasonable attorney’s fees and costs to a
prevailing party.127 A court may award attorney’s fees to a party that
succeeds “‘on any significant issue in litigation which achieves
some . . . benefit . . . [he or she] sought in bringing [the] suit.’”128 A party
does not need to succeed on all issues in order to prevail.129 It is only
necessary to establish that the party has obtained some relief on the merit
of a claim at the “outer boundary of the term ‘prevailing party.’”130
C. GINA Doesn’t Really Help Workers
With its broad language, widely-inclusive relative pool, jury trial,
attorneys’ fees, and costs, how could GINA not be the best thing that ever
happened to a disgruntled employee? Well, it may be. It is possible that
some employee who knows he is on the verge of being fired when GINA
becomes effective will find a way to get his genetic information in front of
the boss before the axe falls. Despite its attempts to protect workers, GINA
is flawed. It doesn’t protect all workers, and it could make the situation
worse for some workers. GINA is not applied fairly to those workers
123. 42 U.S.C. § 2000e-5(g)(1) (2006).
124. Id. § 1981a(a)(1). But see Huckabay v. Moore, 142 F.3d 233, 241 (5th Cir. 1998) (holding
that “§ 1981a does not create a new substantive right or cause of action,” but “provides an
additional remedy for ‘unlawful intentional discrimination . . . prohibited under [other statutes]’”
(quoting 42 U.S.C. § 1981a(a)(1))).
125. 42 U.S.C. § 1981a(b)(3).
126. Id. § 1981a(c)(1).
127. Id. § 2000e-5(k).
128. Farrar v. Hobby, 506 U.S. 103, 109 (1992) (quoting Hensley v. Eckerhart, 461 U.S. 424,
433 (1983)).
129. Easterling v. City of Orlando, No. 6:05-cv-855-Orl-22GJK, 2008 WL 3889612, at *9
(M.D. Fla. Aug. 20, 2008).
130. Id.
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whom it does cover and is likely to result in an increase in insurance rates,
which will be borne across the board by all insureds.
1. GINA Does Not Cover All Employees Who Need Protection
GINA does not protect every worker. Approximately 11.6 million
people in this country are currently unemployed.131 A year ago nearly 2.7
million of them had jobs,132 and, with the current economic crisis,
unemployment lines could be flooded with hundreds of thousands more.
Job-seeking workers would be protected from employment discrimination
in hiring decisions based on genetic information, but most employers deny
that they would test for genetics if they could.133
If employers do want to test, they could easily get around the laws
through a loophole in the ADA regarding genetic testing in the workplace
after an offer is made, but prior to the start of employment.134 To illustrate,
an employer could make a job offer conditioned on medical tests,135 which
might include genetic tests, and later withdraw the offer.136 The prospective
employee might never know if the employer conducted a genetic test or
withdrew the job offer based on the results.137
GINA does not apply to companies with fewer than fifteen
employees.138 In 2006, more than 21.5 million employees, or 18% of the
American private sector workforce, were employed by a company with
zero to nineteen workers.139 Of those, approximately 13 million worked for
companies with fewer than ten employees.140 Clearly, GINA fails to protect
many millions of Americans.
131. U.S. Bureau of Labor Statistics, Economic News Release: Employment Situation
Summary, http://www.bls.gov/news.release/empsit.nr0.htm (last modified Feb. 6, 2009) (last visited
Feb. 17, 2009).
132. Id.
133. Baldas, supra note 53.
134. See id.
135. 42 U.S.C. § 12112(d)(3) (2006).
136. See id.; Baldas, supra note 53; see also Kelly Cahill Timmons, Accommodating
Misconduct Under the American with Disabilities Act, 57 FLA. L. REV. 187, 190 n.14 (2005)
(emphasizing that “[c]ourts have held that persons who have been subjected to medical
examinations and inquiries prohibited by the statute have standing to sue under the ADA, even if
they are not disabled” (citing Roe v. Cheyenne Mountain Conference Resort, Inc., 124 F.3d 1221,
1229 (10th Cir. 1997))).
137. See Baldas, supra note 53.
138. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, § 201(2)(B),
122 Stat. 881, 906 (to be codified at 42 U.S.C. § 2000ff(2)(B)).
139. U.S. Census Bureau, 2006 County Business Patterns: Number of Firms, Number of
Establishments, Employment, and Annual Payroll by Employment Size of the Enterprise for the
United States, All Industries 2006, available at http://www.census.gov/csd/susb/susb06.htm (follow
“U.S., all industries” hyperlink).
140. Id.
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2. An Inherent Unfairness in Protecting Employees
GINA applies only to asymptomatic individuals who are genetically
predisposed to an illness, but it does not protect individuals who are
unfortunate enough to actually manifest the same illness from unknown
factors.141 To use Mark Rothstein’s example of breast cancer, an employee
who tested positive for the BRAC-1 gene would have protection under
GINA as long as she was asymptomatic.142 If she actually developed breast
cancer, then GINA would cease to protect her from employer
discrimination.143 Further highlighting the limited, and unfair, application
of GINA, the employee with genetic markers is protected while the woman
at the next desk who developed breast cancer from unknown factors would
not be protected.144 Rothstein argues this is not a congressional oversight,
but “a symptom of the broader problem of the lack of distributive justice
in an individual health insurance market based on individual medical
underwriting.”145 Such a result is inherently unfair.
3. Insurance Rates Will Increase for Everyone
The insurance industry was very emphatic and direct in its warnings to
Congress that, if GINA passed, insurance rates would increase.146 Janet
Trautwein, Executive Vice President and CEO of the National Association
of Health Underwriters, testified: “It is extremely important that
lawmakers recognize . . . the impact their actions will have on the cost of
health insurance today and in the years ahead. Great care should be taken
to craft legislation that . . . will [not] impede the normal underwriting
process and increase the cost of coverage.”147
Because individual policies tend to be written when a person is sick,148
the individual policy market is the most expensive and the most sensitive
to cost increases, making it critical that an underwriter is able to assess risk
without restriction on significant health data.149 By including the individual
policy market in GINA, and thus denying underwriters the ability to obtain
important familial history from individuals, the underwriter will not have

141. Mark A. Rothstein, Is GINA Worth the Wait?, 36 J.L. MED. & ETHICS 174, 176 (2008).
142. Id.
143. Id.
144. See id. (noting that GINA protects only the 5–10% of women who develop breast cancer
from known genetic factors).
145. Id.
146. Trautwein 2007 Written Statement, supra note 79, at 154.
147. Id. at 156.
148. Id. at 152.
149. Id. at 152–53.

Published by UF Law Scholarship Repository, 2009

21

Florida Law Review, Vol. 61, Iss. 2 [2009], Art. 6

FLO RID A LAW REVIEW

400

[V ol. 61

access to the necessary health information.150 Insurance companies will
therefore rate all policies, group and individual, at the highest cost basis of
a sick person in an individual policy.151 The healthy will subsidize the
unhealthy; the employer-sponsored insured will subsidize the uninsured.
The small-employer market, which employs approximately 38% of all
workers,152 will feel the most significant increases.153 GINA has the
potential to cause the greatest harm to those who are not under its
protection.
4. Employers May Cancel Health Insurance
With increasing frequency, spiraling health insurance costs have forced
companies to drop employer-sponsored health plans or pass on the cost to
employees.154 There is no federal law mandating employer-sponsored
health insurance.155 Health insurers also voiced concern that “[t]he
possibility of virtually unlimited liability could prove to be a financial
hardship for many employers and dampen their enthusiasm to offer
benefits.”156 Faced with demands on all sides, employers may decide that
providing health insurance for employees is simply not worth the expense
and headache. Such a decision could severely strain the burgeoning ranks
of America’s uninsured and push health insurance out of reach of all but
the wealthiest individuals.

150. Id. at 152.
151. Id.
152. See Nat’l Coal. on Health Care, Facts on Health Insurance Coverage,
http://www.nchc.org/facts/coverage.shtml (last visited Feb. 17, 2009) (citing the latest data from
2005).
153. Trautwein 2007 Written Statement, supra note 79, at 154.
154. Nat’l Coal. on Health Care, Facts on Health Insurance Coverage, supra note 152.
155. See Shaw v. Delta Air Lines, Inc., 463 U.S. 85, 91 (1983) (“ERISA does not mandate that
employers provide any particular benefits.”). Employees do not have “any substantive entitlement
to employer-provided health benefits or any other kind of . . . benefits,” and under ERISA,
“[e]mployers . . . are generally free . . . for any reason at any time, to adopt, modify, or terminate”
health care plans entirely. Curtiss-Wright Corp. v. Schoonejongen, 514 U.S. 73, 78 (1995) (citing
Adams v. Avondale Indus., Inc., 905 F.2d 943, 947 (6th Cir. 1990)). See also Wheeler v. Dynamic
Eng’g, Inc., 62 F.3d 634, 637 (4th Cir. 1995); Gable v. Sweetheart Cup Co., 35 F.3d 851, 855 (4th
Cir. 1994); Wise v. El Paso Natural Gas Co., 986 F.2d 929, 935 (5th Cir. 1993) (quoting Phillips
v. Amoco Oil Co., 799 F.2d 1464, 1471 (11th Cir. 1986), cert. denied, 481 U.S. 1016 (1987));
Owens v. Storehouse, Inc., 984 F.2d 394, 397 (11th Cir.1993) (citing Phillips v. Amoco Oil Co.,
799 F.2d 1464, 1471 (11th Cir. 1986), cert. denied, 481 U.S. 1016 (1987)).
156. See Nat’l Ass’n of Health Underwriters, NAHU Position on Genetic Testing,
http://www.nahu.org/legislative/Genetic_position.pdf (last visited Feb. 17, 2009).
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VI. CONCLUSION
It has been a decade since Terri Seargent received the results of her
genetic tests. Congress used her story to argue the need for federal
protection against genetic discrimination. Sadly, GINA would not have
protected Terri. Terri was not asymptomatic; she had already begun
expensive treatments for her disease when she was fired. Further, her small
employer may have been exempt from the provisions of GINA if the
company employed fewer than fifteen people.
GINA has been called “a solution in search of a problem.”157 It does not
solve the problem of employment discrimination based on medical factors
or asymptomatic genetic markers. While GINA protects some workers
from employment-related genetic discrimination, its protection is not
universal. The increased protection to the small percentage of individuals
who purchase individual health insurance policies will be at the expense
of workers in employer-sponsored groups who will be subsidizing the
insurance. Effective protection of genetic information requires significant
changes in the government’s attitude toward providing health care for all
citizens. Legislation is necessary to ensure that “sick people and those
likely to get sick have a right to health care coverage.”158 Protecting
workers from employment discrimination requires Congress to prohibit
employer requests for medical records at any stage, from the offer stage
through employment, unless the request is directly related to job function.
GINA does not accomplish these goals.

157. Andrew Pollack, Genetic-Discrimination Ban Moves Ahead in Congress, N.Y. TIMES,
Apr. 23, 2008, at C1.
158. Rothstein, supra note 141, at 176.
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